These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1677 related articles for article (PubMed ID: 29915603)

  • 1. Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses.
    Hossain F; Majumder S; Ucar DA; Rodriguez PC; Golde TE; Minter LM; Osborne BA; Miele L
    Front Immunol; 2018; 9():1288. PubMed ID: 29915603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allies or Enemies-The Multifaceted Role of Myeloid Cells in the Tumor Microenvironment.
    Haas L; Obenauf AC
    Front Immunol; 2019; 10():2746. PubMed ID: 31849950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy.
    Clappaert EJ; Murgaski A; Van Damme H; Kiss M; Laoui D
    Front Immunol; 2018; 9():2250. PubMed ID: 30349530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression.
    Ostrand-Rosenberg S; Sinha P; Beury DW; Clements VK
    Semin Cancer Biol; 2012 Aug; 22(4):275-81. PubMed ID: 22313874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid cells as orchestrators of the tumor microenvironment: novel targets for nanoparticular cancer therapy.
    Tuettenberg A; Steinbrink K; Schuppan D
    Nanomedicine (Lond); 2016 Oct; 11(20):2735-2751. PubMed ID: 27658725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression.
    Xu W; Dong J; Zheng Y; Zhou J; Yuan Y; Ta HM; Miller HE; Olson M; Rajasekaran K; Ernstoff MS; Wang D; Malarkannan S; Wang L
    Cancer Immunol Res; 2019 Sep; 7(9):1497-1510. PubMed ID: 31340983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mTOR at the Transmitting and Receiving Ends in Tumor Immunity.
    Guri Y; Nordmann TM; Roszik J
    Front Immunol; 2018; 9():578. PubMed ID: 29662490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
    Kamran N; Chandran M; Lowenstein PR; Castro MG
    Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harnessing immune checkpoints in myeloid lineage cells for cancer immunotherapy.
    Park SY; Kim IS
    Cancer Lett; 2019 Jun; 452():51-58. PubMed ID: 30910590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.
    Parker KH; Beury DW; Ostrand-Rosenberg S
    Adv Cancer Res; 2015; 128():95-139. PubMed ID: 26216631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tuning the Tumor Myeloid Microenvironment to Fight Cancer.
    Jahchan NS; Mujal AM; Pollack JL; Binnewies M; Sriram V; Reyno L; Krummel MF
    Front Immunol; 2019; 10():1611. PubMed ID: 31402908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relevance of Interferon Regulatory Factor-8 Expression in Myeloid-Tumor Interactions.
    Abrams SI; Netherby CS; Twum DY; Messmer MN
    J Interferon Cytokine Res; 2016 Jul; 36(7):442-53. PubMed ID: 27379866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD200-CD200R Pathway in the Regulation of Tumor Immune Microenvironment and Immunotherapy.
    Liu JQ; Hu A; Zhu J; Yu J; Talebian F; Bai XF
    Adv Exp Med Biol; 2020; 1223():155-165. PubMed ID: 32030689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions among myeloid regulatory cells in cancer.
    Umansky V; Adema GJ; Baran J; Brandau S; Van Ginderachter JA; Hu X; Jablonska J; Mojsilovic S; Papadaki HA; Pico de Coaña Y; Santegoets KCM; Santibanez JF; Serre K; Si Y; Sieminska I; Velegraki M; Fridlender ZG
    Cancer Immunol Immunother; 2019 Apr; 68(4):645-660. PubMed ID: 30003321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment.
    Ostrand-Rosenberg S; Fenselau C
    J Immunol; 2018 Jan; 200(2):422-431. PubMed ID: 29311384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial: NK-Myeloid Cell Interactions in the Tumor Microenvironment: Implications for Cancer Immunotherapy.
    Wennerberg E; Lundqvist A; Mao Y; Mougiakakos D
    Front Immunol; 2021; 12():718844. PubMed ID: 34276709
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment.
    Carnevalli LS; Ghadially H; Barry ST
    Front Immunol; 2021; 12():633685. PubMed ID: 33953710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NOTCH Signaling in T-Cell-Mediated Anti-Tumor Immunity and T-Cell-Based Immunotherapies.
    Kelliher MA; Roderick JE
    Front Immunol; 2018; 9():1718. PubMed ID: 30967879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment.
    Darragh LB; Oweida AJ; Karam SD
    Front Immunol; 2018; 9():3154. PubMed ID: 30766539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid Metabolic Pathways Confer the Immunosuppressive Function of Myeloid-Derived Suppressor Cells in Tumor.
    Yan D; Adeshakin AO; Xu M; Afolabi LO; Zhang G; Chen YH; Wan X
    Front Immunol; 2019; 10():1399. PubMed ID: 31275326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 84.